"Multiple sclerosis" from_date:2012

icobrain ms for active relapsing–remitting multiple sclerosis icobrain ms for active relapsing–remitting multiple sclerosis Medtech innovation briefing Published: 29 March 2022 www.nice.org.uk/guidance/mib291 pathwaysSummary Summary • The technologytechnology described in this briefing is icobrain ms. It is used to assess disease activity or early signs of disease progression from brain MRI scans in people with active relapsing–remitting multiple sclerosis (MS). • The innovative aspectsinnovative aspects are that icobrain ms quantifies the brain MRI scans and summarises clinically relevant findings in concise structured electronic radiological reports with annotated images. • The intended place in therapyplace in therapy would be when monitoring disease activity in people with active relapsing

Teriflunomide Accord - multiple sclerosis (MS) Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. EMA/CHMP/857461/2022 EMEA/H/C/005960 Teriflunomide Accord (teriflunomide) An overview of Teriflunomide Accord and why it is authorised in the EU What is Teriflunomide Accord and what is it used for? Teriflunomide Accord is a medicine used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation attacks the protective

Ofatumumab (Kesimpta) - multiple sclerosis (MS) Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/130764/2021 EMEA/H/C/005410 Kesimpta (ofatumumab) An overview of Kesimpta and why it is authorised in the EU What is Kesimpta and what is it used for? Kesimpta is a medicine for treating adults with relapsing forms of multiple sclerosis (MS), where the patient has flare-ups (relapses) followed by periods with milder or no symptoms. It is used in patients

Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * * Accessibility * Journals , Jeremy Chataway 1,15,*1 Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK2 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK3 Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK4 Department of Medical Physics

Delta-9-tetrahydrocannabinol and cannabidiol (Sativex) - moderate to severe spasticity due to multiple sclerosis (MS) 1 Published 12 September 2022 1 SMC2473 delta-9-tetrahydrocannabinol 2.7mg and cannabidiol 2.5mg per 100 microlitre spray (Sativex® Oromucosal Spray under review: As treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy. In four phase III/IV studies, Sativex® was associated with greater

Siponimod (Mayzent) - multiple sclerosis (MS) Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/629863/2019 EMEA/H/C/004712 Mayzent (siponimod) An overview of Mayzent and why it is authorised in the EU What is Mayzent and what is it used for? Mayzent is a medicine used to treat adults with an advanced form of MS known as secondary progressive MS (MS). It is used in patients with active disease, which means that patients still have relapses or signs

Fampridine - multiple sclerosis (MS) Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/410661/2020 EMEA/H/C/005359 Fampridine Accord (fampridine) An overview of Fampridine Accord and why it is authorised in the EU What is Fampridine Accord and what is it used for? Fampridine Accord is a medicine used to improve walking ability in adults with multiple sclerosis (MS) who have a walking disability. MS is a disease in which the immune system (the body’s

Worldwide epidemiology of paediatric multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, third edition. Limited data are available on the global rates of paediatric multiple sclerosis. Here, we report on the estimated worldwide prevalence of paediatric MS. We included paediatric prevalence data in 2020-2022 (Multiple Sclerosis International Federation Atlas of MS) and the prevalence of child neurologists (International Child Neurology Association). Data were split into prevalence bands per 100 000. Countries were classified by the WHO Region and World Bank Income. Descriptive analyses were performed. An estimated worldwide prevalence rate was calculated from the 2020-2022 paediatric prevalence data, which was adjusted to reduce outliers' impact

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy. To investigate whether first-line DMT can be safely discontinued in patients with long-term stable MS. This multicenter, rater-blinded, noninferiority randomized clinical trial was conducted between July 1, 2020, and March 20, 2023, at 14 Dutch centers. Data analysis was performed between July 2023 and January 2024. Key inclusion criteria were relapse-onset MS, aged

High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. Vitamin D deficiency is a risk factor for multiple sclerosis (MS) and is associated with the risk of disease activity, but data on the benefits of supplementation are conflicting. To evaluate the efficacy of high-dose cholecalciferol as monotherapy in reducing disease activity in patients with clinically isolated syndrome (CIS) typical for MS. The D-Lay MS trial was a parallel, double-blind, randomized placebo-controlled clinical trial in 36 MS centers in France. Patients were enrolled from July 2013 to December 2020 (final follow-up on January 18, 2023). Untreated patients with CIS aged 18 to 55 years with CIS duration less than 90 days, serum vitamin D concentration

Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial Fatigue is one of the most disabling symptoms reported by people with multiple sclerosis. Although behavioural and pharmacological interventions might be partly beneficial, their combined effects have not been evaluated for multiple sclerosis fatigue, or examined with sufficient consideration of characteristics that might affect treatment response. In this comparative effectiveness research trial, we compared the effectiveness of cognitive behavioural therapy (CBT), modafinil, and their combination for treating multiple sclerosis fatigue. This randomised, analyst-blinded, parallel-arm

Environmental multiple sclerosis (MS) risk factors, genetic MS risk, and brain development in a general paediatric population. Neuroaxonal loss occurs in the early stages of multiple sclerosis (MS), but whether it results from early inflammatory brain damage or an ongoing neurodegenerative process remains unclear. We hypothesise that genetic and childhood environmental risk factors for MS may already have an impact on neurodevelopment before the typical age of onset for MS in the general population. We examined associations and interactions of genetic and environmental risk factors for MS with brain MRI outcomes, including volumetric (n=5350) and diffusion data (n=5649), at ages 9 and 13 years in a large, population-based childhood cohort without MS diagnoses. Polygenic risk scores (PRSs

Individualized Physiotherapy and Activity Coaching in Multiple Sclerosis (IPAC-MS): Results of a Randomized Controlled Trial. To evaluate if a novel intervention involving individualized behavior change strategies delivered by physiotherapists has an effect on physical activity levels in people with multiple sclerosis (MS) who were previously inactive compared with usual care. Prospective . There were 3 consistent features of the intervention: behavior change techniques, recommendations for physical activity, and ongoing physiotherapist support. However, these components were tailored to each participant. The primary outcome was change in physical activity levels at 12 months on the Godin Leisure Time Exercise Questionnaire. Secondary measures included MS symptoms (Multiple Sclerosis Impact

Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition. Recent data suggest increasing global prevalence of multiple sclerosis (MS). Early diagnosis of MS reduces the burden of disability-adjusted life years and associated healthcare costs. Yet diagnostic delays persist in MS care, and even within national unknown. The Multiple Sclerosis International Federation (MSIF) third edition of the Atlas of MS was a survey that assessed the current global state of diagnosis including: adoption of MS diagnostic criteria; barriers to diagnosis with respect to the patient, health care provider, and health system; and existence of national guidelines or national standards for speed of MS diagnosis. Coordinators from

Comparison of diffusion tensor imaging (DTI) tissue characterization parameters in white matter tracts of patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). To investigate the microstructural properties of T2 lesion and normal-appearing white matter (NAWM) in 20 white matter tracts between multiple sclerosis (MS) and neuromyelitis optica spectrum disorder damage in T2 lesion and NAWM areas. The prolonged disease course of MS may aggravate the microstructural damage, and the degree of microstructural damage is further related to cognitive impairment. Microstructure differences between T2 lesion areas and normal-appearing white matter help distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. In multiple sclerosis, lesions rather than

The Effect of Spiritual Care on Hope in Patients with Multiple Sclerosis Referred to the MS Association of Hamadan in Iran. The negative impact of hopelessness on mental health makes multiple sclerosis (MS) disease unmanageable. This study aimed to determine the effect of spiritual care on hope in MS patients. In the present randomized controlled trial study, 70 MS patients were selected from the MS Association of Hamadan, Iran, and randomly allocated to intervention and control groups (35 patients per group). A demographic characteristic form and Snyder's Adult Hope Scale were completed before and after the intervention. Spiritual care was provided in weekly group sessions held for four weeks (45-60 min each). The data were analyzed using SPSS-16. Before the intervention, there were

Explaining the burden of cultural factors on MS disease: a qualitative study of the experiences of women with multiple sclerosis. Multiple sclerosis (MS) is a debilitating, non-traumatic disease that is common among young adults. Cultural factors, as background factors, can affect how patients adapt and their quality of life. This study aimed to explain the burden of cultural factors on Multiple sclerosis. This study was conducted with a qualitative approach and conventional content analysis among women with Multiple sclerosis in Mashhad. The data were collected through semi-structured interviews with women with MS. Fifteen patients with Multiple sclerosis were selected using purposeful sampling. The Graneheim and Lundman method was used to analyze the collected data. The transferability

COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab. To assess comparative effectiveness, safety, and tolerability of off-label rituximab, compared with frequently used therapies approved for multiple sclerosis (MS). A Swedish cohort study of persons with relapsing-remitting MS, age 18 to 75 years at inclusion and with a first therapy start or a first therapy switch between 2011 and 2018. Low-dose rituximab was compared with MS-approved therapies. Primary outcomes were proportions with 12 months confirmed disability worsening and change in MS Impact Scale-29 (MSIS-29) scores, respectively. Secondary endpoints included relapses, therapy discontinuation, and serious adverse events. Analyses used

Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Diroximel fumarate (DRF) and dimethyl fumarate (DMF) are orally administered fumarate disease-modifying therapies (DMTs) for multiple sclerosis (MS). The safety, tolerability, and exploratory efficacy of DRF were evaluated in the phase 3 EVOLVE-MS-1 study . No Evidence of Disease Activity (NEDA-3) is a composite efficacy endpoint used in clinical trials for MS defined as no relapse, no 24-week confirmed disability progression (CDP), no new/newly enlarging T2 lesions, and no new gadolinium-enhancing lesions. As NEDA outcomes in studies may be confounded by initial disease activity, the objective of this analysis was to evaluate NEDA-3 in EVOLVE-MS-1 for newly

Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial. Optical coherence tomography (OCT) inner retinal metrics reflect neurodegeneration in multiple sclerosis (MS). We explored OCT measures as biomarkers of disease severity in secondary progressive MS (SPMS). We investigated people with SPMS from the Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial OCT substudy, analysing brain MRIs, clinical assessments and OCT at baseline and 96 weeks. We measured peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell-inner plexiform layer (GCIPL) thicknesses. Statistical analysis included correlations, multivariable linear regressions and mixed